Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?

C. Dazzi, A. Cariello, G. Rosti, M. Argnani, L. Sebastiani, E. Ferrari, L. Zornetta, G. Monti, P. Nicoletti, M. Baioni, M. Salvucci, E. Scarpi, M. Marangolo

Research output: Contribution to journalArticlepeer-review

Abstract

We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m 2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 μg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of CD34+ cells considered as the target for each high-dose chemotherapy was ≥ 2 × 10 6 /Kg/bw. Fifteen leukaphereses procedures were necessary in group A, while 16 procedures were performed in group B. We did not observe any difference between the two groups in terms of CD34+ cells/μl in the peripheral blood (117 vs 78; p=NS), whereas in the aphereses product we found a significant difference between the two groups of patients in terms of CD34+ cells (6.41 vs 2.89 × 10 6/Kg/bw; p=.009), CFU-GM (82.5 vs 52.3 × 10 4/Kg/bw; p=.04). Interestingly, we noted a different distribution of CD34+/33- cells between the 2 groups (mean value 39% vs 65%; p

Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalLeukemia and Lymphoma
Volume39
Issue number3-4
Publication statusPublished - 2000

Keywords

  • Engraftment kinetics
  • G-CSF
  • High dose cyclophosphamide
  • Non-Hodgkin lymphoma
  • PBPC mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma?'. Together they form a unique fingerprint.

Cite this